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Introduction:
Tamoxifen, the first targeted breast cancer therapy, has shown great success in treating estrogen receptor (ER) positive breast tumors. However, both acquired and de novo resistance to this therapy prevents it from being effective in all situations. While newer therapies, such as aromatase inhibitors, targeting the ER have been developed, some women (such as pre-menopausal women) do not benefit. Therefore, tamoxifen remains an important and clinically useful drug in a subset of ER positive breast cancer patients. Multiple lines of evidence indicate that increased signaling through growth factor pathways, such as the IGF pathway, mediates resistance to tamoxifen. The link between ER and IGF1R leads us to hypothesize that IGF system crosstalk with the ER contributes to tamoxifen resistance. Tamoxifen resistance has thus provided researchers with a reason to investigate other growth factor pathways involved in breast cancer development and progression. As new targeted therapies are being developed, it will be important to examine their benefit with existing therapies. Completion of this project will help address the rationale for combining IGF1R inhibitors with tamoxifen. Further, while clinical trials investigating the combined use of aromatase inhibitors and IGF1R inhibitors have been examined, combined tamoxifen/IGF1R inhibition has not been examined.
Body:
Specific Aim 1: Determine the role of the estrogen receptor in tamoxifen resistant cells.
Determine if tamoxifen resistant cells are stimulated by tamoxifen treatment. 1.2 Determine if the estrogen receptor is expressed and remains functional in tamoxifen resistant cells. 1.3 Determine if tamoxifen resistant cells are responsive to alternate anti-estrogen therapies.
Results
Tamoxifen resistant cells are refractory to tamoxifen treatment.
In order to learn more about endocrine resistance and its implications in breast cancer treatment, tamoxifen-resistant MCF-7L and T47D cells were generated. Cells were cultured in phenol-red-free IMEM containing 5% dextran-cleared-charcoal (DCC) serum and 100 nM 4-OH-tamoxifen for 6 months prior to characterizing cells. Initially, cells ceased to grow; however, after a period of approximately 3 months, cell growth resumed. Cells were passaged for an additional 3 months prior to characterization. After selection, TamR cells survived in the presence of increasing concentrations of tamoxifen; however, parental cells were inhibited with as little as 1 nM tamoxifen (figure 1.1). Further, TamR cells continued to survive over time (up to 14 days) in the presence of 100 nM tamoxifen; whereas parental cells did not grow (figure 1.2) Thus, TamR cells continued to survive and grow in the presence of tamoxifen, even up to concentrations of 1 µM, demonstrating resistance to the drug. MCF-7L and TamR (upper panel) or T47D and TamR (lower panel) cells were plated in monolayer at a density of 10,000 cells/plate in the presence of 1% charcoal stripped serum and increasing concentrations of tamoxifen as indicated. Cells were collected and stained with trypan blue prior to counting using a hemacytometer.
A.
B. 
Day
Tamoxifen resistant cells survive in the presence of tamoxifen over time.
MCF-7L and TamR (upper panel) or T47D and TamR (lower panel) cells were plated in monolayer at a density of 10,000 cells/plate in the presence of 1% charcoal stripped serum and 100 nM tamoxifen. Cells were collected and stained with trypan blue prior to counting using a hemacytometer at the days indicated.
Tamoxifen resistant cells maintain estrogen receptor expression and respond to estrogen treatment.
We began our characterization of the TamR line by determining whether our TamR cells maintained responsiveness to estrogen. Clinically, the majority of tamoxifen resistant breast cancers maintain estrogen receptor expression [1] . Similar to some tamoxifen resistant cancers, TamR cells maintained expression of estrogen receptor (figure 1.3). Estrogen has previously been reported to stimulate proliferation in MCF-7 cells. Interestingly, TamR cells were able to proliferate in response to estrogen to a similar level to parental cells ( figure 1.4) . Further, the pure steroidal antiestrogen fulvestrant was able to inhibit the growth of both TamR and parental cells, indicating the estrogen receptor still plays a role in TamR cells (figure 1.5).
The estrogen receptor contains multiple phosphorylation sites, two prominent sites are serine-118, thought to be phosphorylated by MAPK, and serine-167, thought to be phosphorylated by Akt. In our lab, we have found estrogen is able to phosphorylate the serine-118 site, whereas IGF-I and insulin are able to phosphorylate the serine-167 site. MCF-7L TamR cells had basal phosphorylation of serine-118; however, the site was only phosphorylated in parental cells in response to estrogen treatment. Both insulin and IGF-I were able to phosphorylate serine-167 in parental cells; however, in TamR cells, only insulin was able to phosphorylate the site (figure 1.6). Cells were exposed to charcoal stripped serum for three days prior to harvesting lysates. Lysates were collected from MCF-7L and TamR (left panel) and T47D and TamR (right panel) cells and were separated by SDS-PAGE. Total protein levels of estrogen receptor (ER) and MAPK were assessed using specific antibodies by immunoblotting.
A.
B. MCF-7L and TamR (left panel) or T47D and TamR (right panel) cells were grown in charcoal stripped serum prior to serum starving cells overnight. Cells were treated with 1 nM E2 or 5% FBS and growth was assessed after 5 days using the MTT assay. An unpaired t test was used to compare the difference between untreated and treated samples. *p<0.01
*
MCF-7L TamR
Tamoxifen exerts its action by binding to the estrogen receptor and holding it in an inactive conformation, preventing gene transcription. Therefore, tamoxifen treatment should prevent the transcription of estrogen regulated genes. When we examined the gene expression regulated by ER in TamR cells, we found basal levels of estrogen regulated genes, such as AREG, TFF1, PR, and KIAA0575 were down-regulated (figure 1.7 and data not shown); however, estrogen was able to stimulate transcription of these genes, although not to basal parental levels. Numerous publications list genes regulated by tamoxifen as well as genes upregulated in tamoxifen resistant cells and tumors [2] . Interestingly, we found genes (RAB30, KIAA0922) upregulated in response to estrogen treatment in TamR, but not parental cells ( figure 1.8 ). Although the transcriptional activity of the estrogen receptor was altered in TamR cells, the proliferative response to estrogen did not change. Similar to the clinical situation of tamoxifen resistance where some tumors remain dependent on estradiol, our cells maintained estrogen receptor expression and responded to estrogen treatment. Fulvestrant inhibits the growth of tamoxifen resistant MCF-7L cells. MCF-7L and TamR cells were grown in charcoal stripped serum prior to serum starving cells overnight. Cells were treated with 10 nM insulin or 5% FBS in the presence and absence of 100 nM fulvestrant (ICI) and growth was assessed after 5 days using the MTT assay. Determine the role of the IGF system in tamoxifen resistant breast cancer cells and the responsiveness of tamoxifen resistant cells to anti-IGF therapy.
Determine if IGF signaling is altered in tamoxifen resistant cells. 2.2 Determine if tamoxifen resistant cells displayed altered sensitivity towards IGF1R inhibition and if tamoxifen resistant cells have a biological and biochemical response toward IGF1R inhibition in vitro. 2.3 Determine if tamoxifen resistant tumors are responsive to IGF1R inhibition and if this inhibition is
enhanced when compared to tamoxifen sensitive xenograft tumors.
Tamoxifen resistant cells expressed low levels of IGF1R.
Previous reports have demonstrated a link between IGF1R and ER signaling [3] [4] [5] [6] . Prior to examining the effectiveness of anti-IGF therapy in TamR cells, we examined the IGF signaling pathway and its components. Interestingly, IGF1R protein levels were diminished as measured by Western blot (figure 2.1). Further, TamR cells failed to phosphorylate Akt and MAPK after IGF-I treatment. The cells retained expression of IR and insulin and IGF-II ligand treatment resulted in phosphorylation of Akt and MAPK. Our original hypothesis and specific aims, which postulated IGF1R would be activated in tamoxifen resistance, thusly had to be modified. Our revised statement of work was re-submitted in 2012 (appendix A). To examine whether this change in IGF1R expression was due to decreased transcription, we performed qRT-PCR to examine the message level of IGF1R. Indeed, IGF1R mRNA was decreased in TamR cells compared to parental cells (figure 2.2). Treating TamR cells with estrogen resulted in increased transcription of IGF1R, but did not restore the receptor to parental levels. Insulin receptor mRNA levels were not significantly different between parental and resistant cells (figure 2.2). Further, estrogen treatment did not affect IR levels in either cell line. In agreement with the biochemical data, MCF-7L cells were able to proliferate in response to insulin, IGF-I, and IGF-II; however, TamR cells were only able to proliferate in response to insulin and IGF-II (figure 2.3). Similarly, insulin, IGF-I, and IGF-II were able to stimulate the anchorage independent growth of parental cells; however, TamR cells only grew in response to insulin and IGF-II ( figure 2.4 ). These data demonstrate that tamoxifen resistant cells lack IGF1R expression, but maintain expression of IR and are able to signal, proliferate, and grow through IR. A.
B. Dalotuzumab inhibited signaling, proliferation, and anchorage-independent growth in parental, but not TamR cells.
Dalotuzumab (MK-0646) is a humanized monoclonal antibody that binds the IGF1R. It has been shown to down-regulate IGF1R in vitro and in vivo [7, 8] . In order to examine the ability of the antibody to inhibit IGF-induced signaling, we pretreated MCF-7L parental and TamR cells with 20 µg/ml dalotuzumab for 24 hours prior to stimulating cells with ligand. Dalotuzumab inhibited IGF-I signaling, as measured via Akt and MAPK phosphorylation, in MCF-7L (figure 2.5) and T47D parental cells and had a minimal effect on both insulin and IGF-II signaling. TamR cells did not respond to IGF-I, but pAkt was activated by IGF-II and insulin. Dalotuzumab did not affect response to any of the ligands in TamR cells, presumably due to lack of IGF1R expression. In order to examine if this difference was also biologically relevant, we examined the effect of dalotuzumab on proliferation and anchorage-independent growth using the MTT and soft agar assays, respectively. All IGF system ligands tested induced proliferation in MCF-7L (figure 2.6) and T47D parental cells; however, only proliferation in response to IGF-I was inhibited in the presence of dalotuzumab. In 8
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Absorbance @ 570 nm contrast, insulin and to a lesser extent IGF-II stimulated the proliferation of TamR cells and this proliferation was not inhibited by dalotuzumab. Similarly, all ligands induced the anchorage-independent growth of MCF-7L parental cells (figure 2.7) and dalotuzumab inhibited growth in response to IGF-I and IGF-II. In agreement with the signaling data, both insulin and IGF-II induced the anchorage-independent growth of TamR cells. This growth was not inhibited by dalotuzumab. Thus, dalotuzumab inhibited IGF-induced signaling, proliferation, and anchorage-independent growth in MCF-7L parental cells, but had no effect in TamR cells, presumably due to their lack of IGF1R expression. AEW541 is a dual tyrosine kinase inhibitor (TKI) that targets both IGF1R and insulin receptor. In order to examine the effect of IGF1R TKI's in endocrine resistance, we pretreated MCF-7L parental and TamR cells for three hours with 0.5 µM AEW541 prior to stimulating cells with ligands. AEW541 inhibited insulin, IGF-I, and IGF-II signaling in MCF-7L cells (figure 2.8) and T47D cells. Further, AEW541 was also able to inhibit insulin and IGF-II stimulated phosphorylation of Akt and MAPK in TamR cells. To investigate whether this inhibition was also biologically important, we again examined proliferation and anchorage-independent growth. AEW541 was able to inhibit insulin, IGF-I, and IGF-II stimulated proliferation in MCF-7L (figure 2.9) and T47D cells and insulin and IGF-II stimulated proliferation in TamR cells. Additionally, AEW541 was also able to inhibit insulin, IGF-I, and IGF-II stimulated anchorage-independent growth in MCF-7L parental cells and insulin and IGF-II stimulated anchorage-independent growth in TamR cells (figure 2.10). Thus, AEW541 was able to inhibit signaling, proliferation, and anchorage-independent growth by suppressing both IGF1R and IR function in MCF-7L parental cells. Interestingly, AEW541 was also able to inhibit the growth of TamR cells presumably via suppression of IR signaling. These data show that TKI's, which target both IGF1R and IR, are effective in parental and resistant cells, due to inhibition of IR signaling. MCF-7L and TamR cells were serum starved overnight and pre-treated with 0.3 uM TKI for 3 hours prior to treating the cells with 10 nM insulin, 5 nM IGF-I or 5 nM IGF-II for 10 minutes. Cellular lysates were separated by SDS-PAGE and levels of IGF1R, IR, phosphorylated Akt and MAPK, and total MAPK protein levels were assessed using specific antibodies by immunoblotting. 
Dalotuzumab inhibited estrogen stimulated growth but did not add to tamoxifen-mediated growth inhibition in vivo.
We next examined the effect of dalotuzumab on the in vivo growth of MCF-7L cells. Ovariectomized athymic mice were injected in the second mammary fat pad with MCF-7L cells as previously described [9] . Mice were administered estrogen to stimulate tumor growth and tumors were allowed to establish (tumor volume of ~ 200 mm 3 ) prior to beginning treatment. Dalotuzumab (administered beginning at day 32) inhibited the growth of estrogen stimulated tumors (figure 2.11). To study the combination of tamoxifen and dalotuzumab, estradiol was withdrawn on day 32 and tamoxifen was started. Dalotuzumab treatment began simultaneously with tamoxifen (Tam+dalotuzumab) or when tumors began to grown on tamoxifen alone (Tam dalotuzumab) at approximately day 74. Tamoxifen by itself inhibited the growth of tumors; however, dalotuzumab co-administered with tamoxifen did not further suppress tumor growth. Further, dalotuzumab did not significantly inhibit the growth of tamoxifen-resistant tumors when administered after the tumors began to grow on tamoxifen.
We next sought to determine whether this lack of efficacy of dalotuzumab in tamoxifen treated xenografts was due to decreased IGF1R levels similar to the lack of IGF1R expression as observed in vitro. When tumors reached 1000 mm 3 , mice were sacrificed and tumors were harvested for RNA isolation. Expression of IGF1R mRNA was significantly reduced in tamoxifen treated xenografts when compared to estrogen treated xenografts regardless of dalotuzumab treatment (figure 2.12). Thus, tamoxifen treated xenografts do not benefit from dalotuzumab treatment, due to decreased IGF1R expression. However, estrogen treated xenografts express significantly more IGF1R and benefit from dalotuzumab treatment. These data suggest that the level of receptor expression is important in determining response to dalotuzumab treatment and that estrogen receptor plays an important role in regulating IGF1R expression. 
E2 + Dalo
Global gene expression profiling reveals significant changes between estrogen and tamoxifen treated xenografts.
In order to learn more about tamoxifen resistance in vivo, we performed global gene expression profiling on collected xenograft tumor samples. Specifically, we compared differences between tumors stimulated with estrogen versus tamoxifen. Tumors were harvested during the growth phase of tamoxifen treatment, indicating the tumors were resistant or no longer responding to tamoxifen treatment. We found ~1038 genes to be differentially regulated in estrogen treated compared to tamoxifen resistant tumors using a p<0.05 and fold change >1.5 (figure 2.13). Several network pathways, notably those involved in cellular development/proliferation and gene expression were modulated in tamoxifen resistant xenografts (figure 2.14, 2.15). Ingenuity® pathway analysis revealed significant alterations in ~180 pathways when comparing tamoxifen resistant xenografts to estrogen treated xenografts. Interestingly, two of the pathways found to be disregulated were the IGF-I signaling pathway and the estrogen-dependent breast cancer signaling pathway. Further, one of the ten most highly downregulated genes in tamoxifen resistant xenografts (IGF1R) is a known estrogen regulated gene (figure 2.16). Multiple other estrogen-regulated genes were also found to be significantly decreased in resistant xenografts, including PGR and GREB1. These data support our qPCR findings of decreased IGF1R levels in tamoxifen treated xenografts. Further, these data support our findings from aim 1, which demonstrated classic genomic function of the estrogen receptor was suppressed in tamoxifen resistant cells. -Careful consideration should be taken in the design of clinical trials using anti-IGF1R therapy in order to select the proper patient population which will achieve the most benefit from therapy. 
Reportable Outcomes
growth in TamR cells. In contrast, TKI's, which target both the IR and IGF1R inhibit both the proliferation and anchorage, independent growth of TamR cells. Further, in a xenograft model, tamoxifen treated animals have decreased IGF1R expression in xenografts and do not respond to IGF1R antibody treatment.
Significance
The majority of anti-IGF1R clinical trials are in estrogen receptor-positive patients who have progressed on prior endocrine therapy. Although these agents have been extensively evaluated using in vitro and in vivo modeling systems, their effect in endocrine-resistant models, mimicking the clinical trial scenario, has not been adequately investigated. Our data suggest that IGF1R tyrosine kinase inhibitors may be more effective than IGF1R antibodies in patients resistant to endocrine therapy due to inhibition of IR signaling. Analyze data and submit for publication in peer-reviewed journal.
Task 5: Month 27-35 Perform microarray gene expression analysis on tumors harvested from Task 3. Characterize differences between treatment groups and validate using qRT-PCR. Analyze data and prepare for submission for publication.
Introduction
The first and arguabl y m ost effecti ve targeted therapy for breast cancer involves inhibition of estrogen receptor (EH) function. Tamoxifen, a selective est rogen receptor modu.l ator, has proven efTecti ve in both earl y and advanced stages of breast can cer (1). In addition, d epriving receptors of ligand usin g aromatase inhibitors and degrad ing receptors throu gh pure nonsteroidal a nti-estrogen s have also proven effective. Unfortunately, after initial success, a large portion of these tumors will develop resistance. This has led to the exploration and identification of add itional targeted therapies, namel y against growth factor receptors, such as EGFR, HEH2, and l GF1R.
The IGFlR is a receptor tyrosi ne kin ase that exerts i ts biologic effects th rough binding of the ligands lGF-1 and IGF-ll. Following, ligand binding and receptor activation, adaptor molecules are recr u ited, lead in g to act ivation of downstream pathways, i ncluding the m itogen-acti vated pro- tein kinase (MAPK) and PI3K pathways, ultimately lead ing to proliferation, an giogenesis, resistru1ce to apoptosis, ru1d metastasis (2, 3). The closely related insulin receptor behaves in a similar manner, th rough i ts li gan ds insulin and IGF-ll.
Authors
Cross-talk between the IGF1R an d estrogen receptor has been well-documented and has led to clinical trials investigating the combined use ofiGFlR ru1d EH-inhibitors. Multiple stu d ies have shown that ERa can enhance IG FlR signaling th rough transcri ptional upregu lation of JGFJ R, !RS-1, and !GF-11 (4) (5) (6) (7) (8) . Reciprocally, IGFlR has been shown phosphorylate and activate ER on serine-167 throu gh an S6-kinase mechanism (9) . In adrution to curren t IGF1H inhibitor clinical trials exam ining combined anti-IGFIR, an ti-ER therapies, tr ials are also being conducted in endocrine-resista n t populations.
The role of the IGFlR in cancer has been established ru1d clinical trials evaluating inhibitors to this path way are currentl y und erway (10) . As noted, preclin ical studies have documen ted cross-talk between IGFlR and ER pathways (11), yet clinical trials condu cted prim arily i n endocrine-resistan t patients have been disap pointing (12) . in vitro and in vivo eval uation has been condu cted using endocrine sensit ive cells, with relatively little evidence showi n g the effectiveness of antiIGFlH therapy in endocrine-resistru1t cells.
Two strategies of targeti ng tl1e lGFlR are curren tly being evaluated in clin jcal trials. Monoclonal an tibodies bind to the IGFIH, l eading to receptor internalization and downregulation. Tyrosine kinase inhibi tors bind to the ATP catalytic (18) . Thus, the clinical benefit of using lGFlR/IR tyrosine kinase inhibitors(TKI) may outweigh their potential metabolic side effects. The overall aim of om study was to investigate the effectiveness of anti-IGF therapies using an endocrine resistant model. Herein, we reveal tamox.ifen-resistant cells lack expression of IGFIR, and hence, are unaffected by IGFIR monoclonal antibodies. Tamoxifen-treated xenografts also have reduced levels of lGFIR and mice do not benefit from cornbined treatn1ent with tan1oxifen and dalotuzutnab. Furthermore, complete and successful suppression of IGFlR signaling may require dual-inhibition of IGFlR and PI3K targets, as is currently under study in the clinic. Alternatively, endocrine-resistant patients may require tl1e use of tyrosine kinase inhibitors, which are effective through inhibition of rn. signaling.
Materials and Methods
ltcagents
All chemical reagents were purchased from Sigma-Aldrich w:Uess otherwise indicated lGF-T, IGF-Ll, and insulin were purchased from Novozymes GroPep Umited and Eli Lilly, respectively.
Cell lines and cult ure
All cells were grown at 37"C in a hwnid.ified atmosphere containing 5% C02 and supplemented with 100 U/mL penicillin, 100 Jlg/nlL streptomycin. MCF-7 cells were provided by C. Kent Osborne {Baylor College of Medicine) and maintained in improved MEM Richter's modification mediwn {zinc option) supplemented witl1 5% FBS and 11.25 nmoi/L insnlin. MCF-7 TamR cells were generated by culturing MCF-7 in phenol-red free IMEM (zinc option) supplemented with 11.25 nmol/L insnlin, 5% charcoal/ dextran-treated FBS, and 100 nmol/L 4-0H tamoxifen T47D cells were obtained from ATCCand maintained inMEM supplemented with 5%FBS and 6 ng!mL insulin. T47D TamR cells were generated by culturing T47D cells in phenol-red free IMEM supplemented with 5% charcoal/dextran-treated FBS, and 100 nmol/ L 4-0H tamoxifen. TamRcells were grown in tllepresenceof4-0H tamoxifen for 6 montl1s to allow resistance to develop before characterizing cells. As a control, parental cells were cultured for tl1e same amount of time in regular media. Following the establ.islunent of resistance, ceUs were passed for no more than 3 months.
Antibodies
Horseradish peroxidase-conjugated anti-phosphotyrosine (PY-20) was purchased from BD Biosciences. The ERa antibody used for Western blot analysis was purchased from www.aac~oumals.org
Tamoxifen-Resistant Cells Lose Expression of IGF1 R
Neomarkers Lab Vision. The rn.~ antibody was purchased from Santa Cruz Biotechnology. Antibodies for phosphorylated AJ..1:, IGFlR~. and total and phospho-p44/42 {MAPK/ ERK) were purchased from Cell Signaling Teclmology. Anti-rabbit and anti-mouse horseradish peroxidase-conjugated secondary antibodies were purchased from Pierce.
Growth cu rve a nalys is
Cells were plated at a density of 1 x 10 4 in 6-well plates and allowed to equilibrate overnight. Full medium was replaced with phenol-red free IMEM supplemented with 1% dextrancoated-charcoal (DCC)-FBS. 4-0H tamoxifen was added to cells at concentration and time as indicated in the figmes. Cells were stained witl1 trypan blue and counted using a hemacytometer.
lnltnuno blo t
Cells were plated at a density of3 x 10 5 in 60-mm-diameter dishes and allowed to equilibrate overnight. Full medium was replaced witl1 DCC-treated fetal calf serum for the next 3 to 5 days, after which cells were switched to serum-free medium (SFM) for 24 hours. Upon reaching 70% confluency, cells were treated, placed on ice, washed twice with ice-cold PBS, and lysed with lysis bull"er of 50 mmol/ L Tris-CI (pH 7.4), I % Nonidet P-40, 2 mmoi/L EDTA (pH 8.0), 100 mmol/L NaCl 10 nm10l/L sodiun1 ortl10vanadate, I mmol/L phenylmethylsulfonyl fluoride, 20 Jlg/nlL leupeptin, and 20 Jlg/mL aprotinin). Lysates were clarified by centrifugation at 12,000 rpm for 15 minutes at 4°C. Protein concentrations were detennined using the bicinchoninic acid protein assay reagent kit (Pierce). Cellular protein (50 Jlg) was separated by SDS-PAGE, transferred to a nitrocellulose membrane, and imnnmoblotted according to manufacturer guidelines.
Monolayer growtl1 assay
Cells were plated in 24-well plates at a density of30,000 cells per well, allowed to equilibrate overnight and starved in SFM media for 24 hours. After 5 days of treatment, growth was assessed via the 3-(4,5-dinlethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay as described previously ( 19) . Sixty microliters of 5 mg/ mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliwn bromide solution in SFM was added to each well After incubation for 3 hours at37"C, well~ were aspirated and fonnazan crystals were lysed with 500 JlL of solubilization solution (95% DMSO + 5% lMEM). Absorbance was measured with a plate reader at 570 run using a 650 mn differential filter to assess growt11.
An chorage -indep endent growth
A 1-nlL layer of0.8% SeaPlaque-agarose (BioWhittaker) in 1% PBS-containing growth media was solidified into each well of a !>-well plate. The bottom layer was overlrud with 0.8 m L of a 0.45% top agar mixture for 10,000 cells per well with appropriate treabnent. All plates were incubated at 37"C. After 12 days colony number was assessed on a light microscope witl1 an ocular grid. Five random fields were counted per well and only colonies exceeding two th.irds of a grid square were scored. RNA isolation and quantitative real-time PCR Cells were plated at a density of 1 x 10 6 in 100-mm-diameter dishes, allowed to equilibrate overnigh t, DCC starved for 3 days, and incubated overnight in SFM. Cells were treated with SFM or 1 nmol / L estrad iol for 4 hou rs. Cell ular RNA was isolated using TriPure Reagent according to the manufacturer (Roche). For quality control and to determine concentration, a 260:280 assay was conducted on a spectrophotometer. Forward and reverse prim ers were designed to target the following transcripts: PGR, KIAA0575, INSR, RPLPO and IGFJR.A total of 2 J.lg of RNA was reverse transcribed using the Transcri ptor Reverse Transcriptase Kit, and quantitative PCR was conducted using the Un iversal SYBR G reen Kit accord ing to the manufact urer's recommended protocol (Roche) on an Eppendorf Mastercycler Realplex 4 machine. The relati ve co ncentration of m RNA was calculated using cycle threshold values that were deri ved from a standard curve and normalized to ribosomal protein, large, P 0 as an internal control.
Xenograft growth
AJ I an imal protocols were approved by the Universi ty of Minnesota Institutional Animal Care and Use Com mittee. (5 x 10 6 ) were injected into the mammary fat pad of 5-week-old female ovariectomized athymic mice. One day before injection, mice were administered estrogen via drinking water at a concentration of 1 J.lmol/L as described previously (20) . Tumors were allowed to achieve an average volume of 200 mm 3 before begi nning treatment. Tamoxifen citrate (Sigma-AJd rich) was su bcutaneousl y ad ministered at a dose of 500 J.lg in a peanut oil emulsion daily for 5 of 7 days per week. Dalotu zumab was ad ministered twice weekly via intraperitoneal injection at a dose of 500 J.lg. Control animals were injected with histidine-based buffer and peanut oil alone. Tumor growth was measured bidirectionall y and tumor volumes were calculated using the formula length x breadth 2 /2.
MCF-7L cells
Results
Tarnoxifen-resistant cells are refractory to tarnoxifen treatment but respond to estrogen treatment
To examine the effect of anti-IGF therapy in endocrine resistance, tamoxifen-resistant MCF-7L and T47D cells were generated. After selection, TamR cells survived in the presence of increasing concentrations of tamoxifen; however, parental cells were inhibited with as li ttle as 1 nmoi!L tamoxifen (Fig. 1A) . Thus, TamR cells continued to survi ve and grow in the presence of tamoxi fen, even up to concentrations of 1 J.lmol /L, showing resistance to the d ru g. Similar to some tamoxifen-resistant cancers, TamR cell s maintained expression of estrogen receptor (Fig. lB) . Furthermore, TamR cells were able to proli ferate in response to estrogen (Fig. lC) . When we exrunined gene expression regulated by ER in TamR cells, we found basal levels of estrogen regulated genes such as KIAA0575 (GREBl), PGR (Fig. 1D) , TFFl, AREG, CTSD, and IGFJ R (data not shown) were downregu lated; however, est rogen was still able to stimulate trru1scription of these genes. Similar to the clinical situation of tamoxifen resistance where some tumors remain dependent on estradiol, our cells mai ntained estrogen receptor expression and responded to estrogen treatment.
Tarnoxifen-resistant cells expressed low levels of IGFIR Before examining the effectiveness of anti-IGF therapy in TamR cells, we examined the IGF signaling pathway and its components. Interestingly, IGF1R protein levels were diminished as measured by Western blot (Fig. 2A) . Furthermore, TamR cells failed to phosphorylated Akt and MAPK after IGF-1 treatmen t. The cells retained expression of IR and insulin and IGF-11 ligand treatment resulted in phosphorylation of Akt and MAPK. To examine whether this change in TGF1R expression was because of decreased transcription, we conducted q uantitative real-time PCR (qRT-PCR) to exam ine the message level of TGF1R. Indeed, TGF1R mRNA was decreased in TamR cells compared with parental cells (Fig. 2B) . Treati ng TarnR cells with estrogen resulted in a small increase in IGF1R mRNA, but did not restore the receptor to paren tal levels (Fig. 2B) . lnsulin receptor mRNA levels were not significantl y different between parental and resistant cells (Fig. 2C) . Furthermore, estrogen treatment did not affect IR levels in either cell line. These data show that tamoxifen-resistant cells lack IGF1R expression, but main tain expression of TR and are able to signal through JR.
Dalotuzumab inhibited signaling, proliferation, and anchorage-independent growth in parental, but not TarnR cells Dalotuzumab (MK-0646) is a humanized monoclonal antibody that binds the 1GF1R. It has been shown to downregulate TGFlR in vilro and in vivo (21, 22) . To examine the ability of the antibody to inhibit I GF-induced signaling, we pretreated MCF-7L parental and TamR cells with 20 J.lg/ mL dalotu zumab for 24 hours before stimulating cells with ligand. Dalotuzumab inhibited IGF-1 signaling, as measured via Akt and MAPK phosphorylation, in MCF-7L (Fig. 3A) and T47D (data not shown) parental cells and had a minimal effect on both insuli n and I GF-11 signaling. TamR cells d id not respond to IGF-1, but Akt was activated by IGF-11and insulin. Dalotuzumab did not affect response to any of the ligands in TamR cells, presumabl y because of lack of IGFlR expression. To exam ine if this difference was also biologically relevant, we exan1ined the effect of dalotuzumab on proliferation and anchorage-independent growth using the MTT and soft agar assays, respectively. All IGF system ligands tested induced proliferation in MCF-7L and T470 (data not shown) parental cells; however, only proliferation in response to IGF-1 was inhibited in the presence of dalotu zumab (Fig. 3B) . In con trast, insulin and to a lesser exten t IGF-11 stimulated the proliferation ofTamR cells and this proliferation was not i nhibi ted by dalotuzurnab. Similarly, all ligands i nduced the anchorage-independent growth of MCF-7L parental cells (Fig. 3C) and dalotu zumab inhibited growtll in response to IGF-1 and I GF-11. In agreement wi th the signaling data, both in sulin and IGF-JJ induced the ru1chorage-independent growth of TamR cells. This growth was not i n hi bited by dalotuzumab. Thus, dalotu zumab inhibited IGF-1 induced signaling, proliferation, and anchorageindependent growth in MCF-7L parental cells, but had no 
1-
an endocri ne-resistan t model. Previous i n vestigations i n to the efficacy of anti-IGF therapies have been conducted using endocrine-sensi ti ve cell lines and xenograft models. Because IGFlH is an ER transcriptional target, understanding if IGFlH expression was affected by resistance to tamoxifen has clinical relevance. We found our tamoxifen-resistan t cell lines lacked both protei n and mRNA expression of I G F1H, but main tai ned exp ression of JR. This is i n con tr ast to a report by Westley and colleagues showing that ta moxifen resistance in MCF-7 cells was associated with a dependence on IG F-1 (24) . Th is con trary findi ng may be a resul t of a difference in the way the tamoxifen-resistant cells were generated; these investigators used low serum co nd itions during generation of tamoxifen resistance while we used compete med ia. When cells were selected i n this manner, tamoxifen beca me an EH agonist. Although seemi ngl y contradictory. these find i ngs are consi stent with our own. IGFlH expression requires agonism of EH. In Westley and colleagues, their "ta m oxi fen resistant" ceiJ s tam oxi fen-st imuJated ER function. In ou r tamoxifen-resistant cells, we saw no evidence of agonist ic activi ty stimul ated by ta moxi fen (F ig.
10).
On the basis of prior reports of EH tran scriptional regulation of IGF1H, i t is not surprisi ng that IGF1H expression would be decreased after acu te treatment with a select i ve estrogen receptor modulator such as tamoxifen (25) (26) (27) . I nterestingl y, studies co nducted by Massarweh and colleagues using tamoxifen-resistant xenografts show decreased total levels of IGF1H, but basal phosphorylation of the 1,000 mm 3 m ice were sacrificed and tumors were harvested for RNA isolation. Expression of IGF1H mRNA was significantl y reduced in tamoxifen-treated xenografts when compared with estrogen-treated xenografts regardless of dalotuzumab treatment (Fig. 5B) . Thus, tamoxifen-treated xenografts do not benefit from dalotu zumab treatment, because of decreased IGF1R expression. However, estrogen-treated xenografts express significantl y more IGFlH and benefit from dalotu z um ab treatment. These data suggest that the level of receptor expression is important in determi ning response to dalotu zumab treatment and that estrogen receptor plays an important role in regulating IGF1H expression.
Discussion
The recentl y published resul ts of IGFlR antibodies in clinical trials showi ng lim i ted success in endocri ne-resistan t populations prompted us to i nvestigate their efficacy using receptor (28) . This discordance may be explained by a difference in dosage of tamoxifen in model systems. In our model, tamoxifen is co ntin uousl y ad m in istered to cells, wh ereas, in the Massarweh st udy, ani mals are given tamoxifen 5 times weekJ y, leading to the possibility that ER function is not completely suppressed in this modeL Furthermore, thi s study d id not clearly distingu ish between IGF1H or IH p hospho rylation because the "phosp ho-specific" antibody detects bot h receptors.
The finding that tamoxifen-resistant cells were refractory to I G F1R a nti body treatment u nderscores the importance of using model systems similar to the patient populations the drug will be used i n. Although several studies have showed the efficacy ofiGF1R monoclonal antibodies in breast cancer cells, these cells have been endocri ne sensi tive (21, 23) . The effect of combined anti-estrogen/anti-IGF1H treatment should also take i n to consideration whether the dose of anti-est rogen is sufficient, in and of itself, to suppress IGF1R function via receptor down regulation. Our in vivo resul ts show that tamoxifen treatment results in decreased IGF1R mRNA levels. Ini tial resul ts exam i n i ng the effectiveness of IGFlH antibodies in endocrine-resistant breast cancer populations have not showed a definiti ve positi ve resul t (29, 30) .This may be because of the J ack of 1GF1H expression i n these patient popuJations. A recent stud y examining m RNA expression in a cohort of tamoxifen-resistant patients with breast cancer has showed a decrease i n IGFlR levels i n the recurrent tumors, suggesti ng our findings in vitro may correlate with the clinical scenario (31) . The efficacy of TKJ's in our tamoxifen-resi stant cells underscores the importance of cotargeting the IR, along with the IG F1R. Initially, development of I G F1R i n hibitors aim ed to avoid targetin g the IR, because of poten tial metabolic conseq uences. However, numerous studies by us and oth ers have showed that the IR d oes indeed play a role in cancer biology (14, 18, 29, 32) . Speci ficall y, work by H an ahan and colleagues showed that IGF1R i nhibition using antibodies is only su ccessful in tumors/cells where the IGF lR / TR ratio is high. In addition, they show the IR can actually serve as an escape mechanism, provid in g resistance to I G F1R antibod ies (17) . Further more, work by Haluska and colleagu es has shown that when figitumumab (an TG FlR monoclonal an tibod y) is ad m inistered to patients, th ere is an associated i n crease in plasma i nsulin (33) . This i ncrease i n insulin levels cou ld potentially lead to i ncreased IR signali ng in tumor cells, providing yet another escape mechan ism for th e can cer cells to su rvive. Th ese data are supported by a case report showing increased copy number of IR in a woman wi th metastatic hormonerefractory breast cancer (34) . The role of th e IR in cancer biology has been clearly defi n ed, and the metabolic consequen ces of its inhibition are actively being investigated. A recent study condu cted in m ice sh owed th at an J GF1R/IR TKI alon e or i n combination wi th tamoxi fen did not lead to a significan t chan ge in glucose homeostasis, suggesting the drugs are tolerable. This study also showed the efficacy of the TKI in letrozole resistant xen ografts, support in g our d ata that suggest TKJ 's are more effecti ve th an ant ibod ies i n ta moxifenresistant cells (35) .
Alth ough our data i ndicate IGF lR an tibodies may not be effective i n an end ocrine-resista nt system, this does not mean they have li ttle use. M ul tiple trials are un derway, exam i n ing the use of IGF1R an ti bod ies in end ocr i ne-sensi tive populations. One prom ising area of i nvestigation is inhibiting both the upstream (IGF1R) and downstream (mTOR) components of the I G F1R path way, lead ing to maximal i n h ibition of signali n g. Inh i bition ofiGF1R h as been sh own to sensi tize cell s to mTOR
